GlassScriptPhysician profile
Lynn Q Beard
NPI 1679502801
$1,459.25
in general payments reported to CMS, 2019-2025
26 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $233 · 2021: $298 · 2022: $78.07 · 2023: $181 · 2024: $139 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $437.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.35 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Amarin Pharma, INC. | $162.57 | 2019-2021 | |
| Amgen INC. | $136.38 | 2019-2025 | Otezla, Repatha |
| Astellas Pharma US INC | $127.20 | 2019-2020 | |
| Lilly USA, LLC | $101.54 | 2019-2024 | Mounjaro |
| Glaxosmithkline, LLC. | $83.11 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbott Laboratories | $67.66 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $59.19 | 2019-2025 | |
| Boston Scientific Corporation | $51.45 | 2020-2024 | Wavewriter Alpha Prime 16, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.40 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $40.40 | 2022 | |
| Pfizer INC. | $32.00 | 2019-2023 | |
| Novo Nordisk INC | $29.30 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.63 | 2022 | |
| Bolton Medical INC | $19.15 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $17.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.92 | 2020 | |
| Dexcom, INC. | $16.07 | 2020 | |
| Indivior INC. | $15.96 | 2025 | Sublocade |
| Mannkind Corporation | $14.54 | 2021 | |
| Sanofi Pasteur INC. | $13.30 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.42 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.04 | 2022 | |
| Medtronic, INC. | $11.97 | 2021 | |
| Organon LLC | $7.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Beard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.